Clinical trial
A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD)
NCT00216489 is registered in ClinicalTrials.gov with Janssen Cilag Pharmaceutica S.A.C.I., Greece as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Non Interventional Post Authorization Safety Study (PASS) On The Rabeprazole's Administration To Adults With Gastro-Oesophageal Reflux Disease (GORD)
- Lead sponsor
- Janssen Cilag Pharmaceutica S.A.C.I., Greece
- Phase
- Phase 4
- Overall status
- Completed
- Start date
- March 31, 2003
- Completion date
- November 30, 2005
- Enrollment
- 191 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.